

The Friday night Panel 7:00

Moderator: Julie Nagel, Ph.D. — Chief Operating Officer at Hafion, Inc. Dr. Julie Nagel directs operations and administration for Hafion. She has 20 years of experience in academic commercialization and startups, including leadership positions in commercialization offices, academic translational centers, and as a co-founder of technology-based startup companies, including her current role as co-founder and member of the management team at Hafion, Inc, a startup developing a prophylactic vaccine for *Pseudomonas aeruginosa*. Dr. Nagel consults internationally in academic intellectual asset management, working along the continuum of technology commercialization from academia to startup company formation and development for TreMonti Consulting, LLC. Prior to her current work, Dr. Nagel was the Associate Vice Chancellor for Innovation & Entrepreneurship at the University of Kansas, where she held national leadership positions and Managing Director of the Oncological Sciences Center in Discovery Park at Purdue University. She holds a Ph.D. from the University of Tennessee in Ecology and Evolutionary Biology and did postdoctoral training at the Institute of Toxicology at Wayne State University.



Nick Eisele, PhD – Director of Molecular Biology and Microbiology at Actym Therapeutics. Nick Eisele, Ph.D. is the Director of Molecular Biology and Microbiology at Actym Therapeutics located in Berkeley, CA. Dr. Eisele has over 15 years of experience in the fields of microbial pathogenesis, molecular biology, and immuno-oncology. Prior to Actym, he was Associate Director of Molecular Biology at Atreca, Inc., where he joined as a Scientist in his first industry position. At Atreca, he was responsible for managing the company's hit identification efforts toward finding novel therapeutic antibodies to treat cancer and malaria. Before joining Atreca, Dr. Eisele's academic studies focused on characterizing the host and bacterial factors required for *Salmonella* and *Yersinia* pathogenesis. He received his Ph.D. in Molecular




Microbiology and Immunology at the University of Missouri and completed his postdoctoral studies at Stanford University.



Charlene Emerson, PhD – Lead Scientific Editor of the Roy Blunt NextGen Precision Health at MU. Dr. Charlene Emerson is the lead Scientific Editor of the Roy Blunt NextGen Precision Health building at MU. She works closely with faculty investigators as a writing consultant, helping them craft clear, persuasive, and impactful grant proposals. Dr. Emerson has over 5 years of professional experience in scientific editing, having worked both in a university setting and for the private company, BioScience Writers. She received her Ph.D. from Baylor College of Medicine in Houston, TX, where she was a National Science Foundation Graduate Research Fellow. Despite the appeal of

academic research and the excitement of presenting her molecular genetics work at multiple international research conferences, she chose to transition toward a career in research development. On the journey to her current role, she also gained experience in strategic communications and speechwriting. Dr. Emerson plans to continue her professional journey in research development, finding better ways to support investigators and advance scientific progress, as well as serve as a resource to early career researchers who are looking for a non-traditional career path.



Jared Manse, JD, PhD – Patent Attorney in the Intellectual Property Group, Greensfelder, Hemker & Gale, P.C. Dr. Jared Manse works as a patent attorney at Greensfelder Law Firm, in his native St Louis, Missouri. He has over 15 years combined experience in life science and the law. With his doctoral background in microbiology and immunology, he assists clients in patent prosecution, IP litigation and strategic planning regarding patent infringement and validity.

Jared practices in the biochemical, pharmaceutical and material sciences areas with patent prosecution and licensing and also handles patent and trademark freedom-to-operate analyses and enforcement. Jared was named the Volunteer Lawyer of the Month by the Bar Association of Metropolitan St. Louis in July 2017 for pro bono work for St. Louis tenants facing eviction. He has been named one of the "Ones to Watch" by the The Best Lawyers

in America from 2021-2023.

Jared graduated *magna cum laude* with a degree in biology from Wake Forest University. He subsequently earned his JD from Duke Law School and worked briefly in the IP group of Wilson Sonsini's D.C. office. Jared returned from legal practice to academia following the economic collapse in 2008. Jared studied the molecular underpinnings of bacterial toxins that cause human disease, and earned Ph.D. from the University of Missouri, School of Medicine, completing a joint program in molecular microbiology, immunology and veterinary pathobiology. After completing his PhD, Jared returned to legal work with several St. Louis law firms. Jared is a registered patent attorney with the United States Patent and Trademark Office and admitted to practice in Missouri and the Commonwealth of Virginia.

Katie Thompson, PhD – Co-Founder, Chief Operating Officer, Elemental Enzymes. Dr. Katie Thompson is an entrepreneur, scientist, co-founder, and Chief Operating Officer of Elemental Enzymes, an agricultural biotech company that specializes in the creation of innovative and sustainable agricultural enzymes, peptides, and biochemistries which focus on improving plant performance, health, and yield. Katie received her PhD in Cellular, Molecular, and Developmental biology at the University of Missouri – Columbia while specializing in the characterization of proteins involved in signaling. Soon after graduating, Katie put her passion for scientific advancement to use by supporting the mission and goals of Elemental Enzymes. She has gone "all-in" on the start-up dream and helped lead EE to its current success through performing several key roles including partnership establishment, development of the product portfolio, project management and expansion of the innovation pipeline. Katie's commitment to creating an inclusive and innovative environment has supported Elemental Enzymes through key growth phases and has shaped the overall dynamic culture for which the company is known.

